Emergence and apparent transmission of rimantadine-resistant influenza A virus in families - PubMed (original) (raw)
Clinical Trial
. 1989 Dec 21;321(25):1696-702.
doi: 10.1056/NEJM198912213212502.
Affiliations
- PMID: 2687687
- DOI: 10.1056/NEJM198912213212502
Clinical Trial
Emergence and apparent transmission of rimantadine-resistant influenza A virus in families
F G Hayden et al. N Engl J Med. 1989.
Abstract
To determine whether rimantadine can protect family members from acquiring influenza A viral illness and to assess the possible selection of drug-resistant strains of virus, we conducted a randomized, double-blind, placebo-controlled study in three communities during two influenza seasons. When influenza A occurred in a family, the members (including the index patient) were given either rimantadine (adult oral dose, 200 mg per day) or placebo for 10 days. The presence of illness was monitored by daily recording of symptoms and temperature measurements; infection was determined by isolation of the virus and by serologic studies. Among households with documented influenza A infections, symptomatic illness occurred in one or more contacts in 10 of 28 families treated with rimantadine and in 10 of 209 families treated with placebo. Asymptomatic secondary influenza A infections were found in five families assigned to receive rimantadine and in four families assigned to receive placebo. Rimantadine-resistant strains of influenza A virus (H3N2 subtype) with mutations consisting of single amino acid changes in the M2 protein (residue 27, 30, or 31) were recovered from eight index patients and five contacts treated with rimantadine. There was apparent transmission of drug-resistant strains of virus in six contacts with secondary illnesses in five families. We conclude that when index patients are treated concurrently, rimantadine is ineffective in protecting household members from influenza A infection. If rimantadine is used for both treatment and postexposure prophylaxis in families, rapid selection and apparent transmission of drug-resistant influenza A viruses can occur.
Similar articles
- Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group.
Hayden FG, Gubareva LV, Monto AS, Klein TC, Elliot MJ, Hammond JM, Sharp SJ, Ossi MJ; Zanamivir Family Study Group. Hayden FG, et al. N Engl J Med. 2000 Nov 2;343(18):1282-9. doi: 10.1056/NEJM200011023431801. N Engl J Med. 2000. PMID: 11058672 Clinical Trial. - A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection.
Dolin R, Reichman RC, Madore HP, Maynard R, Linton PN, Webber-Jones J. Dolin R, et al. N Engl J Med. 1982 Sep 2;307(10):580-4. doi: 10.1056/NEJM198209023071002. N Engl J Med. 1982. PMID: 7050702 Clinical Trial. - Children with influenza A infection: treatment with rimantadine.
Hall CB, Dolin R, Gala CL, Markovitz DM, Zhang YQ, Madore PH, Disney FA, Talpey WB, Green JL, Francis AB, et al. Hall CB, et al. Pediatrics. 1987 Aug;80(2):275-82. Pediatrics. 1987. PMID: 3302925 Clinical Trial. - Amantadine and rimantadine for the prevention of influenza A.
Betts RF. Betts RF. Semin Respir Infect. 1989 Dec;4(4):304-10. Semin Respir Infect. 1989. PMID: 2697053 Review. - Managing influenza: amantadine, rimantadine and beyond.
Fleming DM. Fleming DM. Int J Clin Pract. 2001 Apr;55(3):189-95. Int J Clin Pract. 2001. PMID: 11351773 Review.
Cited by
- Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model.
Lee LY, Zhou J, Koszalka P, Frise R, Farrukee R, Baba K, Miah S, Shishido T, Galiano M, Hashimoto T, Omoto S, Uehara T, Mifsud EJ, Collinson N, Kuhlbusch K, Clinch B, Wildum S, Barclay WS, Hurt AC. Lee LY, et al. PLoS Pathog. 2021 May 6;17(5):e1009527. doi: 10.1371/journal.ppat.1009527. eCollection 2021 May. PLoS Pathog. 2021. PMID: 33956888 Free PMC article. - Cost-benefit of stockpiling drugs for influenza pandemic.
Balicer RD, Huerta M, Davidovitch N, Grotto I. Balicer RD, et al. Emerg Infect Dis. 2005 Aug;11(8):1280-2. doi: 10.3201/eid1108.041156. Emerg Infect Dis. 2005. PMID: 16102319 Free PMC article. - In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication.
Kati WM, Montgomery D, Carrick R, Gubareva L, Maring C, McDaniel K, Steffy K, Molla A, Hayden F, Kempf D, Kohlbrenner W. Kati WM, et al. Antimicrob Agents Chemother. 2002 Apr;46(4):1014-21. doi: 10.1128/AAC.46.4.1014-1021.2002. Antimicrob Agents Chemother. 2002. PMID: 11897583 Free PMC article. - The treatment of influenza with antiviral drugs.
Stiver G. Stiver G. CMAJ. 2003 Jan 7;168(1):49-56. CMAJ. 2003. PMID: 12515786 Free PMC article. Review. - The common cold.
Heikkinen T, Järvinen A. Heikkinen T, et al. Lancet. 2003 Jan 4;361(9351):51-9. doi: 10.1016/S0140-6736(03)12162-9. Lancet. 2003. PMID: 12517470 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical